The company expects to assess the antiviral activity, tolerability and safety of ACH-1625 in conjunction with standard of care (SOC) consisting of pegylated interferon alfa-2a and ribavirin.
In the trial, the patients will be randomized to be given once daily doses of 200mg, 400mg or 800mg of ACH-1625 in conjunction with SOC for 12 weeks of dosing.
In previous trials ACH-1625 has demonstrated low single-digit nanomolar potency that is specific to HCV.
Achillion vice president and chief medical officer Elizabeth Olek said initiating the second segment of this Phase 2 clinical trial allows them to build upon the robust RVR results they observed with ACH-1625, and to further augment the safety and efficacy database by taking the opportunity to study multiple doses of ACH-1625.